NCT06901531 2026-03-11
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
Clinical Trials
12 trialsNCT07431281 2026-02-24
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT04379596 2026-02-23
DG-03
AstraZeneca
Phase 2 Recruiting
NCT03504397 2026-02-13
Spotlight
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT06846346 2025-11-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT03777813 2025-11-18
ARION
UNICANCER
Phase 2 Completed
NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
NCT04361708 2025-10-01
I-FLOAT
University of Chicago
Phase 1 Recruiting
NCT07018570 2025-08-26
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
Phase 2 Recruiting
NCT04864067 2025-07-01
NOAHS-ARC
Servicio de Salud Metropolitano Sur Oriente
Phase 2 Active not recruiting
NCT02795988 2025-04-16
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Imugene Limited
Phase 1/2 Completed
NCT01249352 2025-03-31
NICE
Eurofarma Laboratorios S.A.
Phase 2/3 Completed